Last reviewed · How we verify
Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice (REPIN)
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
Details
| Lead sponsor | National Society for Neurosonology and Cerebral Circulation |
|---|---|
| Status | RECRUITING |
| Enrolment | 336 |
| Start date | Wed Feb 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri May 10 2030 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Acute Stroke
Countries
Russia